Literature DB >> 32062289

Ureaplasma parvum causes hyperammonemia presenting as refractory status epilepticus after kidney transplant.

Camille Legouy1, Alice Hu2, Fanny Mochel3, Nicolas Weiss4, Adrien Collin5, Sabine Pereyre6, Mathilde Perrin2, Nicolas Engrand7.   

Abstract

PURPOSE: Alert intensivists about the diagnostic pitfalls arising from hyperammonemia due to Ureaplasma infections in post-transplant patients.
MATERIALS AND METHODS: Clinical observation of one patient. CASE REPORT: A 65-year-old female with a medical history of semi-recent kidney transplant was admitted to the Intensive Care Unit for refractory status epilepticus. There were no lesions on brain imaging. Bacterial cultures and viral PCR of cerebrospinal fluid were negative. The first blood ammonia level measured on day 2 was 13 times the normal level, but biological liver tests were normal. The persistence of elevated ammonia levels led to the initiation of symptomatic ammonia lowering-treatments and continuous renal replacement therapy, which led to its decrease without normalization. An Ureaplasma spp infection was then diagnosed. Levofloxacin and doxycyline were administered resulting in normalization of ammonia levels within 48 h. However repeat MRI showed diffuse cortical cytotoxic edema and the patient remained in a minimally conscious state. She eventually died 4 months later from a recurrent infection.
CONCLUSION: Ureaplasma infection must be suspected in cases of neurological symptoms associated with hyperammonemia without liver failure, following an organ transplant. Only urgent treatment could improve the prognosis and prevent severe neurological damage or death.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Electroencephalography; Hyperammonemia; ICU; Immunosuppressed patient; Kidney transplantation; Refractory status epilepticus; Ureaplasma spp

Mesh:

Substances:

Year:  2020        PMID: 32062289     DOI: 10.1016/j.jcrc.2020.02.003

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  3 in total

1.  Impact of Screening and Treatment of Ureaplasma species on Hyperammonemia Syndrome in Lung Transplant Recipients: A Single Center Experience.

Authors:  Scott C Roberts; Ankit Bharat; Chitaru Kurihara; Rade Tomic; Michael G Ison
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

Review 2.  Hyperammonemia syndrome in immunosuppressed individuals.

Authors:  Scott C Roberts; Waleed Malik; Michael G Ison
Journal:  Curr Opin Infect Dis       Date:  2022-06-01       Impact factor: 4.968

3.  Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database.

Authors:  Alexander Balcerac; Kevin Bihan; Bénédicte Lebrun-Vignes; Dominique Thabut; Joe-Elie Salem; Nicolas Weiss
Journal:  Ann Intensive Care       Date:  2022-06-18       Impact factor: 10.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.